X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
143
Stocks News & Analysis
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,793.40 | 1.40 | -0.02% |
| CAC 40 | 7,935.97 | 24.44 | 0.31% |
| DAX 40 | 23,564.01 | 116.72 | 0.50% |
| Dow JONES (US) | 46,943.35 | 384.88 | 0.83% |
| FTSE 100 | 10,317.69 | 56.54 | 0.55% |
| HKSE | 25,834.02 | 368.42 | 1.45% |
| NASDAQ | 22,397.29 | 291.93 | 1.32% |
| Nikkei 225 | 53,751.15 | 68.46 | -0.13% |
| NZX 50 Index | 13,164.58 | 22.76 | -0.17% |
| S&P 500 | 6,699.90 | 67.71 | 1.02% |
| S&P/ASX 200 | 8,583.40 | 7.80 | 0.09% |
| SSE Composite Index | 4,084.79 | 10.66 | -0.26% |